MACROD2

Across TCGA pan-cancer cohorts, MACROD2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MACROD2 data layer compared with 25 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher MACROD2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MACROD2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

LSCC, PDAC, and CCRCC are the cancer types where MACROD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	All	0.616	0.814	.009	20	view →
PDAC	DFS	Median	All	0.395	0.236	.012	13	view →
CCRCC	DFS	Median	III,IV	0.858	0.562	.020	8	view →
LUAD	DFS	Tertile	III,IV	0.214	0.777	.008	7	view →
GBM	DFS	Quartile	All	0.864	0.648	.010	3	view →
HNSC	DFS	Median	II,III,IV	0.535	0.818	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MACROD2–LSCC (DFS)

Open the LSCC breakdown →